ストックスクリーナーアプリを入手
0.7344
0.74%
-0.0055
前日終値:
$0.7399
開ける：
$0.75
24時間の取引高:
156.97K
Relative Volume:
0.44
時価総額：
$76.25M
収益：
-
当期純損益:
$-13.73M
株価収益率:
-5.6492
EPS:
-0.13
ネットキャッシュフロー:
$-3.92M
1週間 パフォーマンス:
+1.30%
1か月 パフォーマンス:
-5.24%
6か月 パフォーマンス:
-13.60%
1年 パフォーマンス:
+25.93%
1日の値動き範囲:
$0.71
$0.751
1週間の範囲:
$0.68
$0.80
52週間の値動き範囲:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.7344 | 76.25M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive Investors USA
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
Sanctuary Advisors LLC Makes New $864,000 Investment in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - MarketBeat
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tiziana broadens Phase 2 trial for MS therapy - Investing.com India
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions - Proactive Investors USA
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers - The Manila Times
Tiziana Life Sciences Expands Breakthrough MS Drug Trial to Elite U.S. Medical Centers - StockTitan
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7%Here's What Happened - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7% – Here’s What Happened - Defense World
Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump's Loss - Benzinga
Tiziana Life Sciences Secures ALS Trial Funding - Yahoo Finance
Tiziana Life Sciences secures grant for ALS trial - Proactive Investors USA
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Cathie Wood Redirects Elon Musk's DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here's How Oklo, Cameco, Centrus Energy And Other Stocks Performed - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):